Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong · Delayed Price · Currency is HKD 3.300
-0.300 (-8.33%)
Aug 24, 2026, 11:10 AM HKT
Wuhan YZY Biopharma Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 100.07 | 126.28 | 196.68 | 153.52 | 83.09 |
Trading Asset Securities | - | - | - | 15 | 2.5 |
Cash & Short-Term Investments | 100.07 | 126.28 | 196.68 | 168.52 | 85.59 |
Cash Growth | -20.76% | -35.80% | 16.71% | 96.90% | - |
Accounts Receivable | 11.6 | 51.11 | - | - | - |
Other Receivables | 3 | 6.83 | 16.03 | 0.66 | - |
Receivables | 14.6 | 57.94 | 16.03 | 0.66 | - |
Inventory | 3.29 | 4.26 | 5.77 | 10.62 | 8.91 |
Other Current Assets | 13.95 | 32.86 | 31.62 | 59.16 | 31.14 |
Total Current Assets | 131.9 | 221.34 | 250.1 | 238.96 | 125.64 |
Property, Plant & Equipment | 42.04 | 45.41 | 50.38 | 54.55 | 59.96 |
Other Long-Term Assets | 1.07 | 1.09 | 1.14 | 9.34 | 14.55 |
Total Assets | 175.01 | 267.84 | 301.62 | 302.84 | 200.16 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.53 | 6.66 | 3.15 | 3.29 | 10.23 |
Accrued Expenses | 36.54 | 38.65 | 34.99 | 18.96 | 10.65 |
Short-Term Debt | - | - | - | 76.5 | 28 |
Current Portion of Long-Term Debt | 100.01 | 75.82 | 89.5 | - | - |
Current Portion of Leases | 0.25 | 0.36 | 0.46 | 0.17 | 0.4 |
Current Income Taxes Payable | 0.4 | 0.47 | 0.5 | 0.45 | 0.36 |
Current Unearned Revenue | 15.72 | 21.08 | 0.64 | 3.85 | 1.45 |
Other Current Liabilities | 43.1 | 43.1 | 44.58 | 43.74 | 5.82 |
Total Current Liabilities | 200.54 | 186.14 | 173.82 | 146.96 | 56.91 |
Long-Term Debt | 27.5 | 51.08 | - | - | - |
Long-Term Leases | - | 0.09 | 0.15 | - | 0.08 |
Total Liabilities | 228.04 | 237.31 | 173.97 | 146.96 | 56.99 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 193.85 | 193.85 | 193.85 | 182 | - |
Additional Paid-In Capital | 345.01 | 345.01 | 345.01 | 193.38 | 613.6 |
Retained Earnings | -595.12 | -510.39 | -412.79 | -221.09 | -572.44 |
Comprehensive Income & Other | 3.23 | 2.06 | 1.58 | 1.58 | 102 |
Shareholders' Equity | -53.03 | 30.54 | 127.65 | 155.88 | 143.16 |
Total Liabilities & Equity | 175.01 | 267.84 | 301.62 | 302.84 | 200.16 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 127.76 | 127.35 | 90.11 | 76.67 | 28.48 |
Net Cash (Debt) | -27.69 | -1.08 | 106.57 | 91.85 | 57.11 |
Net Cash Growth | - | - | 16.02% | 60.85% | - |
Net Cash Per Share | -0.14 | -0.01 | 0.58 | 0.53 | 0.38 |
Filing Date Shares Outstanding | 193.85 | 193.85 | 193.85 | 182 | 152.11 |
Total Common Shares Outstanding | 193.85 | 193.85 | 193.85 | 182 | 152.11 |
Working Capital | -68.64 | 35.2 | 76.28 | 92 | 68.73 |
Book Value Per Share | -0.27 | 0.16 | 0.66 | 0.86 | 0.94 |
Tangible Book Value | -53.03 | 30.54 | 127.65 | 155.88 | 143.16 |
Tangible Book Value Per Share | -0.27 | 0.16 | 0.66 | 0.86 | 0.94 |
Buildings | 15.4 | 15.4 | 15.04 | 15.04 | 15.04 |
Machinery | 68.15 | 68.16 | 68.33 | 66.81 | 65.46 |
Construction In Progress | 17.56 | 16.85 | 16.85 | 16.85 | 16.85 |
Leasehold Improvements | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |